Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Fk 463
2. Fk-463
3. Fk463
4. Micafungin
5. Mycamine
1. 208538-73-2
2. Funguard
3. Mycamine
4. Fk463 Sodium
5. Fk-463
6. Micafungin Na
7. Micafungin Sodium Salt
8. Fk 463
9. Micafungin Sodium [usan]
10. Is1up79r56
11. Chebi:80105
12. Fk463
13. Sodium;[5-[(1s,2s)-2-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-3-[(1r)-3-amino-1-hydroxy-3-oxopropyl]-11,20,21,25-tetrahydroxy-15-[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] Sulfate
14. Mycamine Sodium
15. Funguard (tn)
16. Mycamine (tn)
17. Mcfg
18. Micafungin Sodium- Bio-x
19. Unii-is1up79r56
20. Micafungin Na [vandf]
21. Micafungin Sodium (jan/usan)
22. Micafungin Sodium [jan]
23. Chembl1237070
24. Ex-a4114a
25. Micafungin Sodium [mart.]
26. Micafungin Sodium [who-dd]
27. Micafungin Sodium Salt [mi]
28. Mfcd08067752
29. S4287
30. Ccg-270668
31. Micafungin Sodium [orange Book]
32. Ac-30600
33. Bm164667
34. D02465
35. Q27149252
36. Pneumocandin A0, 1-((4r,5r)-4,5-dihydroxy-n2-(4-(5-(5-(pentyloxy)phenyl)-3-isoxazolyl)benzoyl)-l-ornithine)-4-((4s)-4-hydroxy-4-(4-hydroxy-3-(sulfooxy)phenyl)-l-threonine)-, Monosodium Salt
37. Pneumocandin A0, 1-(4r,5r)-4,5-ihydroxy-2-4-5-4-(pentyloxy)henyl]-3-soxazolyl]enzoyl]--rnithine]-4-(4s)-4-ydroxy-4-4-ydroxy-3-(sulfooxy)henyl]
| Molecular Weight | 1292.3 g/mol |
|---|---|
| Molecular Formula | C56H70N9NaO23S |
| Hydrogen Bond Donor Count | 15 |
| Hydrogen Bond Acceptor Count | 24 |
| Rotatable Bond Count | 18 |
| Exact Mass | 1291.42029497 g/mol |
| Monoisotopic Mass | 1291.42029497 g/mol |
| Topological Polar Surface Area | 521 Ų |
| Heavy Atom Count | 90 |
| Formal Charge | 0 |
| Complexity | 2580 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 15 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Mycamine |
| PubMed Health | Micafungin (Injection) |
| Drug Classes | Antifungal |
| Drug Label | Mycamine is a sterile, lyophilized product for intravenous (IV) infusion that contains micafungin sodium. Micafungin sodium is a semisynthetic lipopeptide (echinocandin) synthesized by a chemical modification of a fermentation product of Coleophoma e... |
| Active Ingredient | Micafungin sodium |
| Dosage Form | Injectable |
| Route | injection; Iv (infusion) |
| Strength | 100mg/vial; 50mg; 50mg/vial |
| Market Status | Prescription |
| Company | Astellas; Fujisawa Hlthcare |
| 2 of 2 | |
|---|---|
| Drug Name | Mycamine |
| PubMed Health | Micafungin (Injection) |
| Drug Classes | Antifungal |
| Drug Label | Mycamine is a sterile, lyophilized product for intravenous (IV) infusion that contains micafungin sodium. Micafungin sodium is a semisynthetic lipopeptide (echinocandin) synthesized by a chemical modification of a fermentation product of Coleophoma e... |
| Active Ingredient | Micafungin sodium |
| Dosage Form | Injectable |
| Route | injection; Iv (infusion) |
| Strength | 100mg/vial; 50mg; 50mg/vial |
| Market Status | Prescription |
| Company | Astellas; Fujisawa Hlthcare |
Mycamine is indicated for:
* Adults, adolescents 16 years of age and elderly:
- treatment of invasive candidiasis;
- treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;
- prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/l) for 10 or more days.
* Children (including neonates) and adolescents < 16 years of age:
- treatment of invasive candidiasis.
- prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/l) for 10 or more days.
The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate.
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
J02AX05
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INTRAVENOUS - EQ 100MG BA...DOSAGE - INJECTABLE;INTRAVENOUS - EQ 100MG BASE/VIAL
USFDA APPLICATION NUMBER - 21506
DOSAGE - INJECTABLE;INTRAVENOUS - EQ 50MG BAS...DOSAGE - INJECTABLE;INTRAVENOUS - EQ 50MG BASE/VIAL
USFDA APPLICATION NUMBER - 21506
DOSAGE - SOLUTION;INTRAVENOUS - EQ 100MG BASE...DOSAGE - SOLUTION;INTRAVENOUS - EQ 100MG BASE/100ML (EQ 1MG BASE/ML)
USFDA APPLICATION NUMBER - 216142
DOSAGE - SOLUTION;INTRAVENOUS - EQ 150MG BASE...DOSAGE - SOLUTION;INTRAVENOUS - EQ 150MG BASE/150ML (EQ 1MG BASE/ML)
USFDA APPLICATION NUMBER - 216142
DOSAGE - SOLUTION;INTRAVENOUS - EQ 50MG BASE/...DOSAGE - SOLUTION;INTRAVENOUS - EQ 50MG BASE/50ML (EQ 1MG BASE/ML)
USFDA APPLICATION NUMBER - 216142
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
88
PharmaCompass offers a list of Micafungin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Micafungin manufacturer or Micafungin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Micafungin manufacturer or Micafungin supplier.
PharmaCompass also assists you with knowing the Micafungin API Price utilized in the formulation of products. Micafungin API Price is not always fixed or binding as the Micafungin Price is obtained through a variety of data sources. The Micafungin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Micafungin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Micafungin, including repackagers and relabelers. The FDA regulates Micafungin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Micafungin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Micafungin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Micafungin supplier is an individual or a company that provides Micafungin active pharmaceutical ingredient (API) or Micafungin finished formulations upon request. The Micafungin suppliers may include Micafungin API manufacturers, exporters, distributors and traders.
click here to find a list of Micafungin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Micafungin DMF (Drug Master File) is a document detailing the whole manufacturing process of Micafungin active pharmaceutical ingredient (API) in detail. Different forms of Micafungin DMFs exist exist since differing nations have different regulations, such as Micafungin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Micafungin DMF submitted to regulatory agencies in the US is known as a USDMF. Micafungin USDMF includes data on Micafungin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Micafungin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Micafungin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Micafungin Drug Master File in Japan (Micafungin JDMF) empowers Micafungin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Micafungin JDMF during the approval evaluation for pharmaceutical products. At the time of Micafungin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Micafungin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Micafungin Drug Master File in Korea (Micafungin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Micafungin. The MFDS reviews the Micafungin KDMF as part of the drug registration process and uses the information provided in the Micafungin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Micafungin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Micafungin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Micafungin suppliers with KDMF on PharmaCompass.
A Micafungin written confirmation (Micafungin WC) is an official document issued by a regulatory agency to a Micafungin manufacturer, verifying that the manufacturing facility of a Micafungin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Micafungin APIs or Micafungin finished pharmaceutical products to another nation, regulatory agencies frequently require a Micafungin WC (written confirmation) as part of the regulatory process.
click here to find a list of Micafungin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Micafungin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Micafungin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Micafungin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Micafungin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Micafungin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Micafungin suppliers with NDC on PharmaCompass.
Micafungin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Micafungin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Micafungin GMP manufacturer or Micafungin GMP API supplier for your needs.
A Micafungin CoA (Certificate of Analysis) is a formal document that attests to Micafungin's compliance with Micafungin specifications and serves as a tool for batch-level quality control.
Micafungin CoA mostly includes findings from lab analyses of a specific batch. For each Micafungin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Micafungin may be tested according to a variety of international standards, such as European Pharmacopoeia (Micafungin EP), Micafungin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Micafungin USP).
